Iceland-based deCODE genetics announced this week that AstraZeneca
has entered into an agreement to purchase its RoboHTC automated
protein crystallography platform, earmarked for AstraZeneca's drug
discovery sites in Alderley...
Genetics-based drug discovery company CompleGen is to supply Berlex
Biosciences, a US affiliate of German company Schering, with a high
throughput assay system for discovery of compounds active against a
novel target identified by...
Sweden's Biacore International, a specialist in surface plasmon
resonance technologies, has launched its Biacore 3000 GxP (Good
Manufacturing Practice/Good Laboratory Practice) Package, which
will strengthen the system's...
Maintaining sterility is a costly process for drug manufacturers,
but US company Pall Corp says it has introduced a new device that
will allow biopharmaceutical producers to make aseptic connections
instantly, reaping large savings...
Scientists in Australia report this week that they have developed a
powerful software modelling tool, MolSAR, which could have the
potential to reduce drug development costs by up to €28 million per
Dharmacon, a US supplier of RNA and RNA-interference research
products, announced today it has launched Cell Cycle siARRAY, a
collection of ready-to-use siRNA duplexes designed to knock down
112 genes involved in cell cycle regulation.
A series of new flow cytometry products will soon hit the market
with the announcement yesterday from US companies BD Biosciences
and Molecular Probes that, following a recent license agreement, BD
Biosciences Pharmingen has launched...
For years, it has been common wisdom in the pharmaceutical industry
that delivery of drugs via the nose only really works if the
compound can be presented in liquid form. One company begging to
differ is Britannia Pharmaceuticals...
In the second mass spectrometer news of the week, life science
product company Agilent Technologies has introduced an ion trap
mass spectrometer that is approximately 10 times more sensitive
than its predecessor, the company claims.